Advertisement
Enfortumab vedotin plus pembrolizumab benefited patients, regardless of biomarker expression
What updated techniques, counseling and a changing workforce could mean
Treatment involved checkpoint inhibitor, surgery and intravesical therapy
Applications, outcomes and untapped potential
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Retrospective study shows SGLT-2 inhibitors may lead to worse urologic outcomes
Early, individualized diagnosis and comprehensive management key to preserving fertility
Key considerations when diagnosing and managing severe hyponatremia
Medical management remains the starting point for most symptomatic patients seeking treatment
Testosterone deficiency can prove challenging to diagnose and treat
Up to 3 days faster than waiting for urine culture results
Advertisement
Advertisement